Roche CEO Thomas Schinecker told the “Financial Times” that the company’s first anti-obesity drugs would come onto the market “much faster than expected” – possibly by 2028. This booming market is currently dominated by the American company Eli Lilly and the Danish company Novo Nordisk.
In mid-July, Roche once again published positive study data on a potential weight loss drug. This involved the candidate CT-996, which is taken once a day to treat type 2 diabetes and obesity. The drug comes from the portfolio of the American company Carmot, which Roche acquired in December for around $3 billion.
Like several anti-obesity drugs in development, CT-996 belongs to the new class of lipid-lowering drugs, the GLP-1 drugs. It achieved significant results in two sub-studies of an ongoing multi-part Phase I clinical trial. Only shortly before this, Roche had published data on its other obesity candidate CT-388, which had been positively received by analysts and investors.
Schinecker told the Financial Times that Roche could have “around seven” drugs from the Carmot acquisition, some of which are in even earlier stages of development. Roche shares have also recently benefited from the trial data.
The multi-billion dollar market for so-called GLP-1 drugs is becoming increasingly competitive. Many pharmaceutical companies, including industry giants Pfizer and Boehringer Ingelheim, are working on competing products to those of Eli Lilly and Novo Nordisk.
Adapted from German by DeepL/ac
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Life & Aging
Why liberal Switzerland is opposed to the Sarco suicide capsule
Switzerland condemns rocket attack on Golan Heights sports pitch
This content was published on
The Swiss foreign ministry has condemned a rocket attack on a football pitch in the Israeli-occupied Golan Heights, which resulted in the deaths of twelve children and young people.
Groundbreaking claims expected after Crowdstrike IT breakdown
This content was published on
The claims for damages following the recent global IT breakdown of Crowdstrike are expected to be groundbreaking, according to Matthias Stürmer, a professor of digitalisation at Bern University of Applied Sciences.
Swiss National Bank Chairman encourages public engagement in financial issues
This content was published on
Jordan emphasised the importance of financial literacy, noting its relevance in everyday life, such as when looking for a job, taking out a mortgage, preparing for retirement or saving.
No Swiss Federal Council speech at Rütli for August 1 celebrations
This content was published on
Traditionally, a member from the Swiss Federal Council makes an appearance on the Rütli meadow in canton Uri during the August 1 celebrations.
Swiss government investigates historical treatment of Yenish people
This content was published on
The Swiss government has commissioned a legal opinion to clarify Switzerland's role in the treatment of the Yenish community.
Switzerland participates in ASEAN foreign ministers’ meeting
This content was published on
This engagement was part of a four-day tour of Southeast Asia, aimed at advancing the Swiss Federal Council's Southeast Asia Strategy.
Majority of shareholders approve sustainability reports of major Swiss companies
This content was published on
Shareholders have approved the sustainability reports of the largest Swiss companies by a large majority at their annual general meetings.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.